carbonthatcarbonthat
← Every company

Genmab A/S Patents

What Genmab A/S has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.

GMAB on carbonthat →
Filings on file
46
Granted
1
Still pending
45
Filed under
3 names

46 filings

Newest filing first. A pending application has no patent number yet, and most never get one.

InventionPatent
CANCER TREATMENT WITH AN ANTIBODY DRUG CONJUGATEFiled as GENMAB A/S2026-03-25TENG JIN ONGpending
DOSAGE OF ANTIBODY DRUG CONJUGATE RINATABART SESUTECANA61K 47/6849, A61P 35/00, A61K 47/68037, A61K 31/282, A61K 31/502, A61K2039/505, C07K 16/22, C07K 16/28Filed as GENMAB A/S2026-03-24Baiteng ZHAOpending
BISPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD FOR ISOLATION OF SUCHC07K 16/468, C07K 16/2863, C07K 16/2887, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/515, C07K2317/526, C07K2317/732, C07K2317/734, C07K2317/92, C07K2317/94Filed as GENMAB A/S2026-03-16Richard G. Hibbertpending
ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERA61K 47/6843, A61K 47/6851, A61K 47/6849, A61P 35/00, A61K 47/6889, A61K 47/65, A61K 47/68031, A61K 9/0019, A61K 38/05, A61K2039/545, C07K 16/36, C07K2317/56, C07K2317/565Filed as Genmab A/S2026-01-30Reshma Abdulla RANGWALApending
HIGHLY PURIFIED EPCORITAMAB COMPOSITIONSA61P 35/00, C07K 16/2809, A61K 38/00, A61K2039/505, C07K 1/18, C07K 1/34, C07K 1/36, C07K 16/2818, C07K 16/2887, C07K2317/14, C07K2317/31, C07K2317/52, C07K2317/55, C07K2317/71, C07K2317/94Filed as GENMAB A/S2025-11-14Richard G. HIBBERTpending
PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO CD30 AND CD3C07K 16/2809, C07K 16/2878, A61P 35/00, A61K 39/39591, A61K2039/505, C07K2317/24, C07K2317/31, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/70, C07K2317/71, C07K2317/72, C07K2317/73, C07K2317/74, C07K2317/90, C07K2317/92, C07K2317/94Filed as GENMAB A/S2025-09-30Michael Back Dalgaardpending
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 FOR TREATING CANCERC07K 16/2827, C07K 16/2878, A61P 35/00, A61K2039/505, A61K2039/507, A61K2039/545, C07K 16/2818, C07K2317/31, C07K2317/565, C07K2317/76, C07K2317/92Filed as BIONTECH SE2025-09-23Tine M. B. GAZIELpending
AGONISTIC TNF RECEPTOR BINDING AGENTSC07K 16/2878, A61P 37/02, A61P 31/00, A61P 43/00, A61P 3/00, A61P 37/06, A61P 25/00, A61P 29/00, A61P 35/00, A61K2039/505, C07K2317/31, C07K2317/565, C07K2317/75, C07K2317/92, C12N 15/85Filed as GENMAB A/S2025-08-27Ugur Sahinpending
METHODS OF PRODUCING HETERODIMERIC ANTIBODIESC07K 16/00, C07K 16/2809, C07K 16/2863, C07K 16/468, C07K 16/2866, C07K 16/2878, C07K2317/10, C07K2317/14, C07K2317/31, C07K2317/40, C07K2317/51, C07K2317/515, C07K2317/52, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/55, C07K2317/66, C07K2317/94Filed as Genmab A/S2025-08-18Pedro Jose ALFONSO MARTINpending
MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPEC07K 16/30, A61P 35/00, A61K2039/505, C07K 16/32, C07K2317/21, C07K2317/33, C07K2317/732, C07K2317/76, C07K2317/77, C07K2317/92Filed as GENMAB A/S2025-08-15Bart DE GOEIJpending
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEA61K 47/6889, A61P 35/00, A61K 47/68031, A61K 47/6851, A61K 47/6883, A61K 47/68037Filed as GENMAB A/S2025-07-09Haidong LIUpending
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEA61K 47/6889, A61K 47/68031, C07K 5/0815, A61K 47/6843, A61P 35/00, A61K 47/68037, A61K 47/68033, C07D 207/452, C07K 5/0205Filed as GENMAB A/S2025-07-09Haidong LIUpending
COMBINATION TREATMENT OF CD38-EXPRESSING TUMORSA61K 31/69, A61K 39/395, A61K 39/3955, A61P 19/02, A61P 35/00, A61K 31/198, A61K 31/4439, A61K 31/573, A61K 39/39541, A61K 39/39558, A61K 45/06, A61K2039/505, C07K 16/28, C07K 16/2818, C07K 16/2896, C07K2317/34, C07K2317/73, A61K2300/00Filed as GENMAB A/S2025-06-18Jan VAN DE WINKELpending
ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4A61P 35/00, C07K 16/2878, C07K 16/468, A61P 35/04, A61K2039/505, A61K2039/545, C07K 16/40, C07K2317/31, C07K2317/33, C07K2317/52, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/75, C07K2317/76, C07K2317/92, G01N 33/6854, G01N2800/32, G01N2800/52Filed as Genmab A/S2025-06-05Bart E.C.G. DE GOEIJpending
MULTISPECIFIC ANTIBODY AGAINST CD40 AND CD137 IN COMBINATION THERAPY WITH ANTI-PD1 AB AND CHEMOTHERAPYC07K 16/2878, A61P 35/04, A61K 33/243, A61K 31/513, A61K 31/555, A61K 38/00, C07K 16/2818, C07K2317/24, C07K2317/31, C07K2317/35, C07K2317/51, C07K2317/515, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/565, C07K2317/71Filed as Genmab A/S2025-05-29Ugur SAHINpending
ANTIBODIES AGAINST HUMAN CD38A61P 19/02, C07K 16/2878, A61P 35/02, A61P 29/00, A61P 35/00, A61K 39/3955, A61K 45/06, C07K 16/2896, C07K2317/21, C07K2317/33, C07K2317/34, C07K2317/51, C07K2317/515, C07K2317/56, C07K2317/565, C07K2317/732, C07K2317/734, C07K2317/75, C07K2317/76, G01N 33/573, G01N2333/91148Filed as GENMAB A/S2025-05-23Michel DE WEERSpending
CD38 ANTIBODIES AND USES THEREOFA61P 35/02, C07K 16/2896, A61P 37/06, A61P 35/00, A61K 9/0019, A61K 38/193, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/31, C07K2317/35, C07K2317/52, C07K2317/526, C07K2317/565, C07K2317/70, C07K2317/72, C07K2317/732, C07K2317/734Filed as GENMAB A/S2025-04-29Tahamtan AHMADIpending
CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAMEA61K 47/6889, A61K 47/6803, A61K 47/68037, C07K 16/2875, A61K 47/6851, A61K 47/6849, A61P 35/00, A61K 47/68031, A61K 9/0019, A61K 9/08, A61K2039/505, C07K2317/565, C07K2317/77, C07K2317/92Filed as Genmab A/S2025-04-24Xiao SHANGpending
CANCER TREATMENT WITH AN ANTIBODY DRUG CONJUGATEFiled as GENMAB A/S2025-03-25Teng Jin ONGpending
HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOFC07K 16/28, C07K 16/36, A61P 13/08, A61P 43/00, A61P 9/00, A61P 15/14, A61P 1/18, A61P 35/02, A61P 13/10, A61P 15/00, A61P 15/08, A61P 29/00, A61P 1/04, A61P 35/00, A61K 39/395, A61K 39/39533, A61K2039/505, C07K 14/81, C07K2317/21, C07K2317/31, C07K2317/565, C07K2317/732, C07K2317/76, C07K2317/92Filed as Genmab A/S2025-03-12Sandra VERPLOEGENpending
ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOFC07K 16/2878, A61P 35/00, A61K2039/505, C07K 16/4208, C07K2317/565Filed as Genmab A/S2025-03-03Andreea Ioanpending
ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOFC07K 16/2878, A61P 35/00, A61K2039/505, C07K 16/4208, C07K2317/565Filed as Genmab A/S2025-03-03Andreea Ioanpending
ANTIBODIESA61P 35/00, C07K 16/2827, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/572, C07K 16/2803, C07K 16/2809, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/92Filed as GENMAB A/S2025-03-03Louise KOOPMANpending
EGFR AND C-MET BISPECIFIC BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAMEA61K 47/6849, C07K 16/2863, A61K 47/6845, A61K 47/6803, A61K 47/6879, A61P 35/00, A61K 47/68037, A61K 47/68031, A61K2039/505, C07K2317/31, C07K2317/73, C07K2317/76, C07K2317/77, C07K2317/92, C07K2317/94Filed as GENMAB A/S2025-02-27Yang XIAOpending
METHOD FOR PRODUCING A CONTROLLED MIXTURE OF TWO OR MORE DIFFERENT ANTIBODIESC07K 16/00, C07K 1/18, C07K 1/22, C07K 16/065, C07K 16/2803, C07K 16/2887, C07K 16/2893, C07K 16/2896, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/526, C07K2317/90Filed as GENMAB A/S2025-02-05Richard HIBBERTpending
SLITRK6 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAMEC07K 16/18, C07K 16/28, A61K 47/6889, A61K 47/6803, A61K 47/6849, A61P 35/00, A61K 47/68037, A61K 47/68031, A61K 39/395, A61K2039/505, C07K 16/286, C07K 16/4241, C07K2317/35, C07K2317/52, C07K2317/565, C07K2317/77, C07K2317/92Filed as Genmab A/S2025-01-10Wanwan Shenpending
ANTIBODIES AND METHODS FOR PTK7 DETECTIONFiled as GENMAB A/S2024-11-27YANG XIAOpending
METHODS OF TREATING CANCER WITH ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATESA61K 47/6843, A61K 47/6889, A61P 35/00, A61K 33/243, A61K 47/68031, A61K 31/282, A61N 5/10Filed as Genmab A/S2024-11-05Jantine BAKEMApending
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20C07K 16/2809, A61P 35/00, A61K2039/505, A61K2039/545, C07K 16/2887, C07K2317/31Filed as GENMAB A/S2024-10-10Brian ELLIOTTpending
PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAMEA61K 47/6889, A61K 47/68031, C07K 16/40, A61K 47/6851, A61K 47/6849, A61K 47/6887, A61P 35/00, A61K 47/68037, A61K2039/505, C07K 16/28, C07K2317/24, C07K2317/565, C07K2317/567, C07K2317/73, C07K2317/77, C07K2317/92Filed as GENMAB A/S2024-09-26Yang XIAOpending
PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAMEFiled as GENMAB A/S2024-09-26YANG XIAOpending
DOSAGE OF ANTIBODY DRUG CONJUGATE RINATABART SESUTECANFiled as GENMAB A/S2024-09-26BAITENG ZHAOpending
ULTRAFILTRATION / DIAFILTRATION PURIFICATION METHODSFiled as GENMAB A/S2024-09-18HAIDONG LIUpending
METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATEA61K 39/39558, A61K 45/06, C07K 16/36, A61K 47/6843, A61K 47/6803, A61K 47/6849, A61P 35/00, A61K 47/68031, A61K 39/395, A61K2039/507, A61K2300/00, C07K 16/2818Filed as Genmab A/S2024-08-08Reshma Abdulla RANGWALApending
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMAA61K 31/454, A61K 39/395, A61K 39/3955, C07K 16/2809, A61P 7/00, A61P 35/02, A61P 35/00, A61K 31/519, A61K2039/507, A61K2039/545, C07K 16/2887, C07K2317/24, C07K2317/31, C07K2317/52, C07K2317/565Filed as GENMAB A/S2024-07-25Christopher W. L. CHIUpending
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMAA61K 31/573, A61K 39/395, C07K 16/2809, A61K 47/6811, A61K 47/6867, A61P 35/02, A61P 35/00, A61K 31/675, A61K 31/704, A61K 39/3955, A61K 39/39558, A61K 45/06, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545, A61K2300/00, C07K 16/2803, C07K 16/2887, C07K2317/24, C07K2317/31, C07K2317/52, C07K2317/565Filed as GENMAB A/S2024-07-25Christopher W. L. CHIUpending
ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4A61P 35/00, C07K 16/2878, C07K 16/468, A61P 35/04, A61K2039/505, A61K2039/545, C07K 16/40, C07K2317/31, C07K2317/33, C07K2317/52, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/75, C07K2317/76, C07K2317/92, G01N 33/6854, G01N2800/32, G01N2800/52Filed as Genmab A/S2024-06-26Bart E.C.G. De Goeij12351650
METHODS OF TREATING CD20 EXPRESSING B-CELL CANCERSA61K 39/395, C07K 16/2809, C07K 16/2887, A61P 35/02, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545, A61K2039/55511, C07K2317/31, C07K2317/565Filed as GENMAB A/S2024-05-15Nurgul KILAVUZpending
HIGHLY PURIFIED EPCORITAMAB COMPOSITIONSA61P 35/00, C07K 16/2809, A61K 38/00, A61K2039/505, C07K 1/18, C07K 1/34, C07K 1/36, C07K 16/2818, C07K 16/2887, C07K2317/14, C07K2317/31, C07K2317/52, C07K2317/55, C07K2317/71, C07K2317/94Filed as GENMAB A/S2024-05-15Richard G. HIBBERTpending
METHODS OF TREATING LYMPHOMA WITH BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20A61K 31/138, C07K 16/2809, C07K 16/2887, A61P 35/02, A61P 35/00, A61K 31/573, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/31, C07K2317/73Filed as Genmab A/S2024-04-12Tommy R. LIpending
ANTIBODIESC07K 16/30, A61K 47/6851, A61K 47/6849, A61K 47/6879, A61P 35/00, A61K 47/68031, C07K 16/114, A61K2039/505, C07K 16/2809, C07K2317/21, C07K2317/31, C07K2317/33, C07K2317/34, C07K2317/51, C07K2317/56, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/92, C12N 15/79, G01N 21/7703, G01N 33/54373, G01N2021/772, G01N2021/7779Filed as Genmab A/S2024-03-26David SATIJNpending
METHODS OF TREATING CD20 EXPRESSING B-CELL CANCERSFiled as GENMAB A/S2024-03-25Nurgul KILAVUZpending
BISPECIFIC ANTIBODIES AGAINST HER2C07K 16/32, A61K 47/6849, A61K 47/6855, A61K 47/6879, A61K 39/395, A61K 45/06, A61K2039/505, C07K 16/1063, C07K 16/2809, C07K 16/2863, C07K 16/2887, C07K 16/468, C07K2317/21, C07K2317/24, C07K2317/30, C07K2317/31, C07K2317/33, C07K2317/41, C07K2317/526, C07K2317/53, C07K2317/55, C07K2317/73, C07K2317/732, C07K2317/734, C07K2317/77, C07K2317/92, C07K2317/94Filed as GENMAB A/S2024-03-05Bart DE GOEIJpending
VARIANTS OF CD38 ANTIBODY AND USES THEREOFA61P 35/00, C07K 16/2896, A61K 47/6911, A61P 37/00, A61P 35/02, A61K2039/505, C07K2317/21, C07K2317/24, C07K2317/52, C07K2317/526, C07K2317/56, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/73, C07K2317/732, C07K2317/734, C07K2317/92Filed as GENMAB A/S2024-01-23Bart DE GOEIJpending
MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCERC07K 16/2878, C07K 16/468, A61P 35/00, A61K2039/505, A61K2039/507, A61K2039/54, C07K 16/2818, C07K2317/31, C07K2317/33, C07K2317/52, C07K2317/565, C07K2317/567, C07K2317/71, C07K2317/76Filed as GENMAB A/S2024-01-12Ugur SAHINpending
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEFiled as GENMAB A/S2024-01-11HAIDONG LIUpending

Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.

More on GMAB

Company overviewEverything on GMAB in one place, with the price.SEC filingsWhat GMAB's 8-Ks say happened: results, departures, auditor changes.Who owns itEvery manager reporting a position in GMAB.Funds holding itWhich funds and ETFs hold GMAB, and how big a bet.

Related datasets

Corporate LobbyingWhat companies spend lobbying Congress, and on what.Lobbying FirmsThe shops companies hire, and who else they represent.Government ContractsWhat federal agencies pay those same companies.Revolving DoorFormer staff now lobbying, and who they worked for.